Inter J Stomatol ›› 2017, Vol. 44 ›› Issue (5): 614-618.doi: 10.7518/gjkq.2017.05.024
• Reviews • Previous Articles
Wang Qi, Chen Xiyan, Wen Yong.
CLC Number:
| [1] Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer[J]. EMBO Rep, 2014, 15(6):642-656. [2] Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer[J]. Cell, 2015, 163(4):811-828. [3] Johnson R, Halder G. The two faces of Hippo: tar-geting the Hippo pathway for regenerative medicine and cancer treatment[J]. Nat Rev Drug Discov, 2014, 13(1):63-79. [4] Heinemann A, Cullinane C, De Paoli-Iseppi R, et al. Combining BET and HDAC inhibitors synergisti-cally induces apoptosis of melanoma and suppresses AKT and YAP signaling[J]. Oncotarget, 2015, 6(25): 21507-21521. [5] Lin Z, Zhou P, von Gise A, et al. Pi3kcb links Hippo-YAP and PI3K-AKT signaling pathways to promote cardiomyocyte proliferation and survival[J]. Circ Res, 2015, 116(1):35-45. [6] Straßburger K, Tiebe M, Pinna F, et al. Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP[J]. Dev Biol, 2012, 367(2):187-196. [7] Li XJ, Leem SH, Park MH, et al. Regulation of YAP through an Akt-dependent process by 3,3’-diindolyl-methane in human colon cancer cells[J]. Int J Oncol, 2013, 43(6):1992-1998. [8] You B, Yang YL, Xu Z, et al. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells[J]. Oncotarget, 2015, 6(6): 4357-4368. [9] Yu S, Cai X, Wu C, et al. Adhesion glycoprotein CD44 functions as an upstream regulator of a net-work connecting ERK, AKT and Hippo-YAP path-ways in cancer progression[J]. Oncotarget, 2015, 6 (5):2951-2965. [10] Suzuki A, Pelikan RC, Iwata J. WNT/β-catenin signaling regulates multiple steps of myogenesis by regulating step-specific targets[J]. Mol Cell Biol, 2015, 35(10):1763-1776. [11] Saito-Diaz K, Chen TW, Wang X, et al. The way Wnt works: components and mechanism[J]. Growth Factors, 2013, 31(1):1-31. [12] Barry ER, Morikawa T, Butler BL, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP[J]. Nature, 2013, 493(7430):106- 110. [13] Heallen T, Zhang M, Wang J, et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size[J]. Science, 2011, 332 (6028):458-461. [14] Rosenbluh J, Nijhawan D, Cox AG, et al. β-Catenin-driven cancers require a YAP1 transcriptional com-plex for survival and tumorigenesis[J]. Cell, 2012, 151(7):1457-1473. [15] Varelas X, Wrana JL. Coordinating developmental signaling: novel roles for the Hippo pathway[J]. Trends Cell Biol, 2012, 22(2):88-96. [16] Hatzis P, van der Flier LG, van Driel MA, et al. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells[J]. Mol Cell Biol, 2008, 28(8):2732-2744. [17] Konsavage WM Jr, Kyler SL, Rennoll SA, et al. Wnt/β-catenin signaling regulates Yes-associated protein(YAP) gene expression in colorectal carcinoma cells[J]. J Biol Chem, 2012, 287(15):11730-11739. [18] Barry ER, Morikawa T, Butler BL, et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP[J]. Nature, 2013, 493(7430):106- 110. [19] Wang J, Park JS, Wei Y, et al. TRIB2 acts down-stream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function[J]. Mol Cell, 2013, 51 (2):211-225. [20] Hussey GS, Chaudhury A, Dawson AE, et al. Identi-fication of an mRNP complex regulating tumori-genesis at the translational elongation step[J]. Mol Cell, 2011, 41(4):419-431. [21] Xie Q, Chen J, Feng H, et al. YAP/TEAD-mediated transcription controls cellular senescence[J]. Cancer Res, 2013, 73(12):3615-3624. [22] Varelas X, Sakuma R, Samavarchi-Tehrani P, et al. TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal [J]. Nat Cell Biol, 2008, 10(7):837-848. [23] Fujii M, Toyoda T, Nakanishi H, et al. TGF-β syner-gizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth[J]. J Exp Med, 2012, 209(3):479-494. [24] Xia Y, Chang T, Wang Y, et al. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients[J]. PLoS One, 2014, 9(3):e91770. [25] Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus[J]. Cell, 2003, 113(6):685-700. [26] Tsukazaki T, Chiang TA, Davison AF, et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor[J]. Cell, 1998, 95(6):779-791. [27] Dobolyi A, Vincze C, Pál G, et al. The neuroprotec-tive functions of transforming growth factor beta proteins[J]. Int J Mol Sci, 2012, 13(7): 8219-8258. [28] Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling[J]. Cell, 1997, 89(7):1165-1173. [29] Ferrigno O, Lallemand F, Verrecchia F, et al. Yes-associated protein(YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-β/Smad signaling[J]. Oncogene, 2002, 21(32):4879-4884. [30] Piersma B, Bank RA, Boersema M. Signaling in fib-rosis: TGF-β, WNT, and YAP/TAZ converge[J]. Front Med(Lausanne), 2015, 2:59. |